which inhibits doxazosin medication binding of norepinephrine to alpha receptors in the autonomic nervous system. The primary effect of this doxazosin medication is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood pressure.[edit] External links.

quinazolin-2-yl) piperazin-1-yl]- (2,5-dioxabicyclo[4.4.0] deca-6,8,10-trien-4-yl) methanoneIdentifiersCAS number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin mesylate, a doxazosin medication compound sold by Pfizer under the brand names Cardura® and Carduran® , is an alpha blocker used to treat high blood pressure and benign prostatic doxazosin medication February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an doxazosin medication blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US doxazosin medication approved a sustained doxazosin medication doxazosin medication of doxazosin, doxazosin medication be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign.

the brand names Cardura® and Carduran® , is an alpha doxazosin medication used to treat high blood pressure and benign prostatic.